TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Consensus Recommendation of "Buy" from Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine research firms that are currently covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $11.79.

Several equities research analysts have commented on the stock. Roth Capital raised shares of TriSalus Life Sciences to a "strong-buy" rating in a research note on Monday, November 11th. Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences in a research report on Tuesday, December 17th. They issued an "overweight" rating and a $10.00 target price for the company. Roth Mkm reaffirmed a "buy" rating and set a $11.00 price target on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Northland Securities started coverage on shares of TriSalus Life Sciences in a research note on Friday, October 25th. They issued an "outperform" rating and a $12.50 target price for the company. Finally, Canaccord Genuity Group dropped their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Friday, November 15th.

Insider Buying and Selling

In other news, CFO James Emmett Young bought 6,000 shares of the company's stock in a transaction that occurred on Wednesday, February 5th. The shares were acquired at an average price of $5.65 per share, for a total transaction of $33,900.00. Following the completion of the acquisition, the chief financial officer now directly owns 30,000 shares in the company, valued at approximately $169,500. This represents a 25.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Mary T. Szela purchased 4,826 shares of the business's stock in a transaction on Monday, January 27th. The shares were acquired at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the completion of the acquisition, the chief executive officer now directly owns 429,503 shares in the company, valued at approximately $2,327,906.26. This represents a 1.14 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired a total of 124,868 shares of company stock worth $575,843 in the last ninety days. 32.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TLSI. Walleye Capital LLC bought a new stake in TriSalus Life Sciences in the 3rd quarter worth about $66,000. MSD Partners L.P. purchased a new stake in TriSalus Life Sciences in the third quarter worth $184,000. Vestcor Inc bought a new stake in shares of TriSalus Life Sciences in the third quarter valued at $108,000. Geode Capital Management LLC lifted its position in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock valued at $924,000 after buying an additional 62,542 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences during the 3rd quarter worth $92,000. Institutional investors and hedge funds own 2.58% of the company's stock.

TriSalus Life Sciences Trading Up 0.9 %

Shares of TLSI traded up $0.05 during trading hours on Monday, hitting $5.38. 14,766 shares of the stock traded hands, compared to its average volume of 28,678. The business has a fifty day moving average of $4.66 and a 200-day moving average of $4.74. The firm has a market capitalization of $164.04 million, a PE ratio of -2.16 and a beta of 0.51. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $10.42.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.